LONG-TERM SURVIVAL OF THE FIRST BIOLOGIC TREATMENT IN PSORIATIC ARTHRITIS AND THE EFFECT OF THE SELECTED TREATMENT ON DRUG SURVIVAL; TURKBIO REGISTRY
S. B. Kocaer1, T. Yüce İnel1, Y. Erez1, A. Köken Avşar1, S. Uslu1, A. Karakas1, S. Gulle1, G. Can1, İ. Sari1, M. Birlik1, E. Dalkiliç2, Y. Pehlivan2, S. Akar3, A. Cefle4, M. A. Öztürk5, S. Yolbaş6, N. Yilmaz7, S. Erten8, N. Akkoc9, F. Onen1
1Dokuz Eylul University Faculty of Medicine, Rheumatology, Izmir, Turkey
2Uludag University Faculty of Medicine, Rheumatology, Bursa, Turkey
3Katip Celebi University Faculty of Medicine, Rheumatology, Izmir, Turkey
4Kocaeli University Faculty of Medicine, Rheumatology, Kocaeli, Turkey
5Gazi University Faculty of Medicine, Rheumatology, Ankara, Turkey
6Inonu University Faculty of Medicine, Rheumatology, Malatya, Turkey
7Bilim University Faculty of Medicine, Rheumatology, Istanbul, Turkey
8Yildirim Beyazit University, Rheumatology, Ankara, Turkey
9Celal Bayar University Faculty of Medicine, Rheumatology, Manisa, Turkey
Background: Currently, biologic treatments are used effectively in patients with psoriatic arthritis (PsA).
Objectives: The aim of this study was to evaluate and compare long-term drug survival of the first biologic treatments including adalimumab, certolizumab, etanercept, golimumab, infliximab, secukinumab and ustekinumab in patients with PsA.
Methods: PsA patients, electronically registered at each visit in the TURKBIO database between 2011 and 2019 were included in the study. PASW 18.0 for Windows was used for statistical analysis. Drug survival rates were calculated by Kaplan Meier method.
Results: 355 patients (227 women; axial PsA = 48, peripheral PsA = 307) were included in the study (
Table 1
). Adalimumab was the most commonly used first biologic treatment (n=125; 37.6%). The rate of drug survival was found to be 0.75 at month 60 in patients receiving the first biologic treatment (
Figure 1
). There was no significant difference in drug survival rate between tumor necrosis factor alpha inhibitor (TNFi) and non-TNFi biologic drugs (p=0.56). No difference was also found in drug survival rates between each biologic treatment.
Initial demographic and clinical datas of patients with PsA
PsA Patients (n=355)
Females, n (%)
227 (63,9)
Age of diagnosis, years*
34,6 (27-42)
CRP baseline*
6 mg/ L (3-15)
ESR baseline*
24 mm/h (10-38)
Smoking, n (%)
Current
99 (28,5)
Never
192 (55,3)
Previous
56 (16,2)
HLA B27 positivity,n (%)
41 (26,4)
First biologic agent, n (%)
-TNFi
332 (95,4)
Adalimumab
Etanercept
125 (37,6)
80 (24,1)
Golimumab
52 (15,6)
Certolizumab
44 (13,3)
Infliximab
31 (9,4)
- Other biologic agents
16 (4,6)
Secukinumab
13 (81,3)
Ustekinumab
3 (18,7)
*
median (min-max
)
Conclusion: The results of this study establish that more than half of patients with PsA can remain in their initial biologic treatment over a long term. It has been observed that the choice of biologic treatment did not effect the drug survival in PsA.
Disclosure of Interests: None declared
Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1161
